•
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the commercial launch of their co-developed amyloid-beta (Aβ) monoclonal antibody, Leqembi (lecanemab), in South Korea. The Ministry of Food and Drug Safety (MFDS) had previously approved the drug in May 2024 for the treatment of adult…
•
Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator, Bayer Co.Lab Berlin, which will initially house MyoPax GmbH, a local startup specializing in muscle regeneration therapies through stem cell and gene editing technologies. Expanding Bayer’s Global Incubator NetworkBayer Co.Lab Berlin joins Bayer’s global network…
•
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded with the approval of the draft for the 2025 edition of the Chinese Pharmacopoeia (ChP 2025 Edition). The approval paves the way for the imminent implementation of the new edition. Enhancements in Scientificity and StandardizationThe…
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its drug Arcalyst (rilonacept), indicated for the treatment of cryo-pyrin-associated periodic syndromes (CAPSs), including familial cold autoimmune syndrome (FCAS) and muckle-well syndrome (MWS). Understanding CAPS and Its SubtypesCAPS is a…
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), for the treatment of FRα positive platinum-resistant ovarian cancer (PROC) in patients who have…
•
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III study for its drug MRX-4 in combination with contezolid as sequential therapy for complex skin and soft tissue infections. The study successfully met its primary efficacy endpoint, demonstrating good clinical and microbiological efficacy. The regimen’s…
•
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for 2024, which includes 91 new drugs. Among these, 89 were added through negotiation/pricing bidding, and 2 were winning bids in the volume-based procurement (VBP). Concurrently, 43 drugs that had been supplanted in clinical use or…
•
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen…
•
The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of medical services through the establishment of a robust first visit and referral system. The plan outlines a timeline for the development of a smooth two-way referral system within compact medical consortia, including urban medical groups…
•
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals from the National Medical Products Administration (NMPA) for its two Category 1 products: KYHY2302 cream for mild to moderate plaque psoriasis and KYHY2303 tablets for recurrent or refractory malignant hematological tumors. KYHY2302 Cream for Plaque…
•
The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage Drug Prices,” which call for all localities to temporarily suspend the acceptance of applications for direct online listing of in-shortage drugs before January 1, 2025. Suspension of Direct Online Listing and Price Increase RequestsThe guidelines…
•
China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing approval from the European Commission (EC) for its programmed death-1 (PD-1) inhibitor, Tevimbra (tislelizumab). The drug is now approved for use in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC)…
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has approved another indication for its product Daxxify (daxibotulinumtoxin, RT002). The type A botulinum toxin is now approved for the treatment of adult cervical muscle tone disorders in China. Background on…
•
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing Technology, Chinese Academy of Sciences, has announced receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Category 1 drug, PR00012. Phase I…
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing for Ameile (almonertinib) has been accepted for review by the National Medical Products Administration (NMPA). The epidermal growth factor receptor (EGFR) inhibitor is now under review for the first-line treatment of locally advanced or metastatic…
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study in China. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CMS-D005 in healthy and overweight and obese adult subjects. Dual…
•
The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport EP Medtech Co., Ltd, (SHA: 688351) has been granted marketing approval by the National Medical Products Administration (NMPA) in China. Global Recognition and Enhanced FeaturesDeveloped by Stereotaxis, the Genesis RMN system has already received approval…
•
GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European Commission (EC) for its Menveo vaccine, a Meningococcal Group A, C, W-135, and Y conjugate vaccine (MenACWY vaccine), in a single-vial, fully liquid presentation. This formulation is designed for the prevention of invasive meningococcal disease…
•
China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand Life Sciences, appointing the latter as the sole commercial promotion service provider in mainland China, Hong Kong, and Macau for TenNor’s rifasutenizol (TNP-2198), a treatment for Helicobacter pylori (H. pylori) infection. Financial Terms and ResponsibilitiesUnder…